Xeltis
Latest round
- Series D
Last raised
- Feb 2023
Total raised
- $124M
Investors
- 7
About Xeltis
Based in the Netherlands, Xeltis AG specializes in innovative vascular implants aimed at improving outcomes for patients with cardiovascular conditions through bioresorbable solutions, designed to facilitate natural healing and tissue regeneration. Xeltis AG, founded in 2006 and co-founded by Laurent Grandidier and Martijn Cox, focuses on developing bioresorbable vascular grafts and patches for cardiovascular applications. The company is headquartered in Eindhoven, Netherlands. Eliane Schutte serves as the CEO.V. Xeltis specializes in transformative vascular implants designed to address a range of cardiovascular conditions. Their core product offerings revolve around bioresorbable vascular grafts and patches that facilitate the natural healing process by promoting tissue regeneration. These innovative implants are engineered to integrate with the body’s own tissues, offering a long-term solution for patients suffering from vascular diseases. The primary end users of Xeltis’ products include hospitals, cardiovascular surgeons, and healthcare providers across Europe and North America, where they aim to improve surgical outcomes and enhance the quality of life for patients. By aligning their products with the needs of healthcare professionals, Xeltis addresses critical use cases such as congenital heart defects and arterial blockages, contributing to advancements in the field of cardiovascular therapy. Xeltis generates revenue through direct sales of its innovative vascular implants to healthcare institutions and practitioners. The transaction structure typically involves B2B sales, where hospitals and surgical centers purchase the implants for use in various cardiovascular procedures. Revenue is driven by the demand for Xeltis' flagship products, which are marketed based on their unique capacity to promote natural healing and tissue integration. Pricing plans for the implants are structured to reflect their advanced technology and clinical benefits, allowing healthcare providers to access these solutions for their patients. The company maintains a strategic focus on fostering relationships with healthcare professionals to facilitate the adoption of their products, which plays a critical role in their revenue generation strategy. Xeltis AG is actively working on new products aimed at enhancing its vascular implant offerings.
Who invested in Xeltis
7 investors across 4 rounds
See all investors in Xeltis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Xeltis
Who invested in Xeltis?
Xeltis has 7 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Xeltis raised?
Xeltis has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Xeltis last raise money?
Xeltis's most recent round on record is a Series D, in Feb 2023.
What does Xeltis do?
Based in the Netherlands, Xeltis AG specializes in innovative vascular implants aimed at improving outcomes for patients with cardiovascular conditions through bioresorbable solutions, designed to facilitate natural healing and tissue regeneration.
Where is Xeltis headquartered?
Xeltis is headquartered in Eindhoven, Netherlands.
Which VCs invest in companies like Xeltis?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back medical devices & equipment companies at Xeltis's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series D
Raising like Xeltis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.